Efficacy and Safety of Fingolimod in an Unselected Patient Population.

Efficacy and Safety of Fingolimod in an Unselected Patient Population.

Fingolimod is a first in class oral compound approved for the treatment of relapsing-remitting multiple sclerosis (RR-MS). The aim of this study was to evaluate clinical and neuroradiological responses to fingolimod as well as the safety and tolerability in RR-MS patients in clinical practice. In ad...

Full description

Bibliographic Details
Main Authors:	Maria Rasenack, Jonathan Rychen, Michaela Andelova, Yvonne Naegelin, Christoph Stippich, Ludwig Kappos, Raija L P Lindberg, Till Sprenger, Tobias Derfuss
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2016-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC4703383?pdf=render

Similar Items

Cerebellar abnormalities contribute to disability including cognitive impairment in multiple sclerosis.
by: Katrin Weier, et al.
Published: (2014-01-01)

Fingolimod in children with Rett syndrome: the FINGORETT study
by: Yvonne Naegelin, et al.
Published: (2021-01-01)

Safety of generic fingolimod
by: O. M. Koval, et al.
Published: (2018-03-01)

Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis
by: Nuria Cerdá-Fuertes, et al.
Published: (2023-02-01)

Safety and Efficacy of Fingolimod in Treatment-Naïve Multiple Sclerosis Patients
by: James J. Marriott
Published: (2011-01-01)

Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results
by: Jeffrey A. Cohen, et al.
Published: (2019-09-01)

Safety and Efficacy of Fingolimod in Iranian Patients with Relapsing-remitting Multiple Sclerosis
by: Fatemeh Yavari, et al.
Published: (2021-03-01)

Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis
by: Gajofatto A, et al.
Published: (2015-12-01)

Efficacy and Safety of Fingolimod in Daily Practice: Experience of an Academic MS French Center
by: Thomas Roux, et al.
Published: (2017-05-01)

Practice Effects of Mobile Tests of Cognition, Dexterity, and Mobility on Patients With Multiple Sclerosis: Data Analysis of a Smartphone-Based Observational Study
by: Tim Woelfle, et al.
Published: (2021-11-01)

Cocapture of cognate and bystander antigens can activate autoreactive B cells
by: Sanderson, Nicholas S. R., et al.
Published: (2018)

Wearable Sensor Technologies to Assess Motor Functions in People With Multiple Sclerosis: Systematic Scoping Review and Perspective
by: Tim Woelfle, et al.
Published: (2023-07-01)

Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
by: Rozita Doosti, et al.
Published: (2021-04-01)

Brain atrophy measurement over a MRI scanner change in multiple sclerosis
by: Tim Sinnecker, et al.
Published: (2022-01-01)

Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis
by: Martin Diebold, et al.
Published: (2022-12-01)

Cliticization as Unselective Attract
by: Lea Nash, et al.
Published: (2002-12-01)

Longitudinal changes of deep gray matter shape in multiple sclerosis
by: Charidimos Tsagkas, et al.
Published: (2022-01-01)

Weight Loss and Fingolimod
by: Nefati Kıylıoğlu
Published: (2017-12-01)

Review Of The Safety, Efficacy And Tolerability Of Fingolimod In The Treatment Of Pediatric Patients With Relapsing-Remitting Forms Of Multiple Sclerosis (RRMS)
by: Feng J, et al.
Published: (2019-11-01)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
by: Ilaria Callegari, et al.
Published: (2023-01-01)

Death Anxiety and Attitudes towards Death in Patients with Multiple Sclerosis: An Exploratory Study
by: Jara Francalancia, et al.
Published: (2021-07-01)

Safety and Efficacy of Fingolimod Compared to Placebo in the Treatment of Relapsing Multiple Sclerosis: A Systematic Review and Meta-analysis Study
by: Hamidreza Dehghan, et al.
Published: (2021-02-01)

Toxicidad hepática por fingolimod
by: juan sebastian theran leon, et al.
Published: (2024-02-01)

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: A phase 3b, open-label study
by: Gold, R, et al.
Published: (2014)

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
by: Gold, R, et al.
Published: (2014)

Cardiac Safety of Fingolimod 0.5 mg during the First Dose Observation in 4-Month, Open-Label, Multi-Center FIRST Study in Patients with Relapsing MS
by: Comi, G, et al.
Published: (2012)

Modulation of Cardiac Autonomic Function by Fingolimod Initiation and Predictors for Fingolimod Induced Bradycardia in Patients with Multiple Sclerosis
by: Kai Li, et al.
Published: (2017-10-01)

Erratum to: Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.
by: Gold, R, et al.
Published: (2014)

Real-world evidence on the safety and effectiveness of fingolimod in patients with multiple sclerosis from Taiwan
by: Chih-Chao Yang, et al.
Published: (2021-01-01)

Fingolimod para la esclerosis multiple
by: Jose Luis Bustos Sánchez, et al.
Published: (2013-09-01)

Fingolimod para la esclerosis multiple
by: Jose Luis Bustos Sánchez, et al.
Published: (2013-09-01)

Fingolimod w leczeniu stwardnienia rozsianego
by: Marek Juszczak, et al.
Published: (2010-09-01)

Oral sildenafil (Viagra™) in male erectile dysfunction: use, efficacy and safety profile in an unselected cohort presenting to a British district general hospital.
by: Boustead Gregory, et al.
Published: (2002-04-01)

Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis
by: Celia Camacho-Toledano, et al.
Published: (2022-11-01)

Efficacy of the Chinese version interpretation bias modification training in an unselected sample: A randomized trial.
by: Fan Zhang, et al.
Published: (2021-01-01)

Cardiac safety of fingolimod 0.5 mg during the first-dose observation in a 4-month, open-label, multicentre FIRST study in relapsing multiple sclerosis patients
by: Gold, R, et al.
Published: (2012)

Evaluation of pregnancy outcomes in patients with multiple sclerosis after fingolimod exposure
by: Yvonne Geissbühler, et al.
Published: (2018-11-01)

Personalized medicine in multiple sclerosis: hope or reality?
by: Derfuss Tobias
Published: (2012-10-01)

The efficacy and safety of fingolimod plus standardized treatment versus standardized treatment alone for acute ischemic stroke: A systematic review and meta‐analysis
by: Peng Bai, et al.
Published: (2022-06-01)

The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study.
by: Guillermo Izquierdo, et al.
Published: (2017-01-01)